Intraosseous vs. Intravenous Vancomycin Prophylaxis for Diabetic Foot Amputations: A Rando
he purpose of this study is to compare the effects of two different ways of giving the antibiotic vancomycin to prevent infections in patients undergoing amputation due to diabetic foot infection. Patients with diabetes often have poor blood circulation in their legs, which may prevent standard intravenous (IV) antibio
| Condition(s) | Diabetic Foot Disease, Diabetic Foot Infection, Diabetic Amputation Foot Wound |
|---|---|
| Status | Recruiting |
| Phase | Phase 4 |
| Study type | Interventional |
| Summary | he purpose of this study is to compare the effects of two different ways of giving the antibiotic vancomycin to prevent infections in patients undergoing amputation due to diabetic foot infection. Patients with diabetes often have poor blood circulation in their legs, which may prevent standard intravenous (IV) antibiotics from reaching the surgical site in high enough concentrations. This study compares: Intraosseous (IO) Administration: Giving the antibiotic directly into the bone at the amputation site during surgery. Intravenous (IV) Administration: Giving the antibiotic through a standard vein infusion before surgery. The researchers want to find out if the intraosseous method: Reduces the rate of surgical site infections compared to the standard IV method. Causes fewer changes in kid |
| Who can participate | Inclusion Criteria: PATIENTS AGED 18 YEARS AND OLDER. DIAGNOSED WITH TYPE 1 OR TYPE 2 DIABETES MELLITUS. SCHEDULED FOR TRANSTIBIAL (BELOW-KNEE) AMPUTATION DUE TO DIABETIC FOOT INFECTION. WILLING AND ABLE TO PROVIDE WRITTEN INFORMED CONSENT. Exclusion Criteria: KNOWN ALLERGY OR HYPERSENSITIVITY TO VANCOMYCIN. PRE-EXISTING RENAL INSUFFICIENCY (BASELINE SERUM CREATININE \> 2.0 MG/DL OR GFR \< 30 ML/MIN). PREGNANCY OR BREASTFEEDING. PREVIOUS SURGICAL INTERVENTION OR AMPUTATION ON THE SAME EXTREMITY. BODY MASS INDEX (BMI) OVER 35. CONTRAINDICATION TO STANDARD PROPHYLACTIC ANTIBIOTICS. INABILITY TO LOCALIZE THE TIBIAL TUBERCLE FOR INTRAOSSEOUS INFUSION. IMMUNOCOMPROMISED STATUS (HIV, HEPATITIS C, END-STAGE RENAL DISEASE, DIALYSIS, ACTIVE CHEMOTHERAPY OR RADIOTHERAPY). USE OF IMMUNOSUPPRESSIVE DR |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Başakşehir Çam & Sakura City Hospital |
| Locations | Istanbul, Istanbul, Turkey (Türkiye) |
| Start date | 2025-09-03 |
| NCT ID | NCT07338773 |
| Official listing | https://clinicaltrials.gov/study/NCT07338773 |